Detalhe da pesquisa
1.
Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia.
Nat Commun
; 15(1): 5180, 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38890323
2.
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multi-omic Target Deconvolution.
J Mol Biol
; 435(10): 168085, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37019174
3.
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
J Immunother Cancer
; 10(11)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442911
4.
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
Leukemia
; 35(9): 2581-2591, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33633313
5.
Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies.
Cancer Immunol Res
; 6(9): 1008-1013, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29980538
6.
A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase.
Sci Rep
; 8(1): 9472, 2018 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29930256